Founded in 2018, Merand Pharmaceuticals, Inc. is a clinical stage, privately held corporation (Delaware registered), which is developing microRNAs for unmet clinical needs in patients with vascular diseases. Its first product will target patient populations with poor blood flow to the lower extremities, those suffering from peripheral artery disease (PAD).
The Company completed a pre-Investigational New Drug (IND) meeting with the FDA and is completing the work needed to begin its first-in-human studies in early 2023. Merand believes that its product, MPMI-93, has the potential to be disease modifying, unlike the current available therapy, and is being positioned for Breakthrough Therapy designation and accelerated approval.
In work carried out in the Company’s co-founder and Chief Medical Officer, Dr. Brian Annex’ laboratory, MPMI-93 was shown to promote blood vessel growth leading to increased blood flow in the more challenging mouse models of PAD, while also reducing inflammation in the affected ischemic muscle. The ability to improve blood flow in ischemic tissue with this miRNA has been verified by three independent labs, demonstrating the feasibility of using MPMI-93 clinically to treat PAD.
Internationally Recognized Physician/Scientist in PAD & Seasoned Biotech Execs